Loading company…
StapleBio develops next-generation nucleic acid medicines that target disease-linked RNA molecules.
StapleBio develops pharmaceuticals using nucleic acid technology designed to target disease-linked RNA molecules and regulate protein production. Founded in 2021 and based in Kumamoto, Japan, the company is at the Series A stage. In April 2024, it raised JPY 460 million led by Diamond Medino Capital, Mitsubishi UFJ Capital, and Summit Pharmaceuticals International Corporation.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in